- Report
- August 2025
- 199 Pages
Global
From €3154EUR$3,545USD£2,723GBP
€3504EUR$3,939USD£3,026GBP
- Report
- August 2025
- 189 Pages
Global
From €3154EUR$3,545USD£2,723GBP
€3504EUR$3,939USD£3,026GBP
- Report
- August 2025
- 371 Pages
Global
From €5205EUR$5,850USD£4,494GBP
- Report
- October 2024
- 200 Pages
Global
From €4403EUR$4,949USD£3,802GBP
Motilin receptor agonists are a class of drugs used to treat gastrointestinal disorders. They act on the motilin receptor, a G-protein coupled receptor found in the gastrointestinal tract, to stimulate the release of hormones that control gastrointestinal motility. This helps to reduce symptoms such as nausea, vomiting, abdominal pain, and bloating. Motilin receptor agonists are used to treat a variety of gastrointestinal disorders, including gastroparesis, functional dyspepsia, and irritable bowel syndrome.
Motilin receptor agonists are available in both oral and injectable forms. Commonly prescribed oral motilin receptor agonists include erythromycin, domperidone, and itopride. Injectable motilin receptor agonists include erythromycin and metoclopramide.
Motilin receptor agonists are an important part of the gastrointestinal drug market, providing relief to those suffering from gastrointestinal disorders.
Some companies in the Motilin Receptor Agonist market include Pfizer, Novartis, Merck, and Sanofi. Show Less Read more